The Food and Drug Administration has approved Amneal Pharmaceuticals' lanreotide injection, and the company says the product launched immediately, adding another competitor to a specialty injectable that generated nearly a billion dollars in U.S. brand sales over the past year.
Amneal announced the approval on Sept. 18 for its 120 mg/0.5 mL single-dose prefilled syringe, which references Ipsen's Somatuline Depot and carries Competitive Generic Therapy designation from the FDA. In its announcement of the approval and launch, the company said the product "adds another material growth driver to our Affordable Medicines business," in the words of Srinivas Kone, senior vice president and chief scientific officer for that unit.
Lanreotide is not a household drug, but for the patients who depend on it, the monthly injection is central to daily life. It is used to treat acromegaly, to improve progression-free survival in eligible patients with advanced gastroenteropancreatic neuroendocrine tumors, and to reduce the need for rescue therapy in carcinoid syndrome.
The part of this story that deserves attention is not the approval itself. It is what happened the last two times a non-brand lanreotide was cleared.
Inside the Approval and the Market It Enters
Amneal's product is not the first non-brand lanreotide. Cipla received FDA approval for a lanreotide injection in December 2021 through the 505(b)(2) new drug application pathway, covering 60 mg, 90 mg, and 120 mg strengths, and announced that approval in a statement on receiving final approval for lanreotide injection. The same company then obtained final approval for an abbreviated new drug application for the same strengths in May 2024, described as therapeutically equivalent to Somatuline Depot.
Brand sales did not collapse. U.S. annual sales for Somatuline Depot were $983 million for the 12 months ended July 2026, according to IQVIA figures cited in Amneal's announcement. Using the same measure, Cipla reported about $867 million for the 12 months ended October 2021 and roughly $898 million for the 12 months ended March 2024.
In other words, a specialty injectable has now absorbed two earlier non-brand approvals across five years, and its reported U.S. revenue has grown rather than shrunk. That is the context any patient should have before assuming a new approval means a smaller bill next month. Amneal is the second company to bring a non-brand lanreotide to the U.S. market, making three lanreotide products in all.
The Competitive Generic Therapy designation explains why the FDA wanted more entrants. Congress created the pathway in 2017 for drugs with what the statute calls inadequate generic competition, which the agency defines as no more than one approved product in the active section of the Orange Book. The FDA's guidance on competitive generic therapies describes expedited development and review for designated products and a 180-day exclusivity period for qualifying first applicants. Long-acting injectables are exactly the category the incentive targets, because the manufacturing is difficult and the patient populations are small.
Reasons Patients May Not See Lower Bills Right Away
Several structural features separate a generic approval from a household saving.
Lanreotide is given as a deep subcutaneous injection, usually in a clinical setting, which means it is typically billed under a patient's medical benefit rather than the pharmacy benefit. Medical benefit drugs are frequently purchased by the practice and billed to the insurer, so the price a patient experiences flows through coinsurance percentages and site-of-care contracts rather than a pharmacy counter price.
Substitution also does not happen automatically in that setting. A pharmacist can swap an equivalent generic tablet at the counter under state substitution laws. A practice choosing which lanreotide to stock is making a purchasing and contracting decision, and payers may steer through prior authorization criteria that list preferred products by name.
Supply is the other variable. Amneal said it has dedicated, large-scale in-house manufacturing capacity for the product, which is relevant because complex injectables have historically been vulnerable to shortages when a single supplier stumbles. A third manufacturer improves resilience even in a year when it does not move prices.
Neither Amneal nor Ipsen has published a patient-facing price for comparison, and Amneal's announcement did not state one. Whether this entry changes net costs will not be visible until payer formularies and practice purchasing decisions settle over the coming months.
Steps for Patients on Monthly Injections
Nobody should change or stop a prescribed injection schedule because a new product exists. Lanreotide controls hormone levels and, in neuroendocrine tumor patients, is part of a treatment plan built around imaging and oncology follow-up. Any substitution belongs to the treating endocrinologist or oncologist.
Patients facing high coinsurance can ask specific, useful questions. Ask the prescribing office whether the practice stocks more than one lanreotide product and whether the plan lists a preferred one. Ask the insurer whether the drug falls under the medical or pharmacy benefit, since that determines the cost-sharing math. Ask about prior authorization requirements before a scheduled injection rather than after a denial.
Patients whose prior authorization is denied can appeal, and the prescribing office can submit clinical documentation supporting medical necessity. Manufacturer patient assistance programs and independent nonprofit foundations serving neuroendocrine tumor and pituitary disorder patients may help with coinsurance for those who qualify. Medicare beneficiaries should ask whether the drug falls under Part B, which is typical for clinician-administered injectables.
Patients should also report side effects. Lanreotide can reduce gallbladder motility and contribute to gallstone formation, and it can cause changes in blood sugar and a slowed heart rate. Full prescribing information is available in the package insert that accompanies the product.
What happens next depends on decisions that are not public yet: how payers position the new product on formularies, whether practices shift purchasing, and whether Ipsen responds on price. The FDA lists designated approvals on its competitive generic therapy approvals list, which is where a further entrant would look before filing.
The newest confirmed fact is a third lanreotide option on the U.S. market. The most reasonable action for affected households is a specific conversation with the prescribing office about product choice and cost-sharing. The central uncertainty is whether this approval finally moves a price that two previous ones did not.
Key Questions Answered
What did the FDA approve? Amneal's lanreotide injection, 120 mg/0.5 mL, in a single-dose prefilled syringe referencing Somatuline Depot, with Competitive Generic Therapy designation. The company says it launched immediately.
What is lanreotide used for? Acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, where it reduces the need for rescue therapy.
Is this the first generic? No. Cipla received approval through the 505(b)(2) pathway in 2021 and an abbreviated new drug application approval in 2024.
Will patients pay less? That is not yet known. Brand U.S. sales were $983 million for the 12 months ended July 2026 despite earlier competitors, and no patient-facing price comparison has been published.
Why do costs move slowly for injectables? These products are usually billed under the medical benefit and administered in a clinical setting, so pharmacy-counter substitution rules do not apply.
What is Competitive Generic Therapy designation? A pathway created in 2017 for drugs with inadequate generic competition, offering expedited review and, for qualifying first applicants, 180 days of exclusivity.
What should patients do now? Keep the prescribed schedule, and ask the prescribing office and insurer which product is preferred, which benefit it falls under, and what prior authorization requires.
